Introduction {#s1}
============

Autophagy is an evolutionarily conserved intracellular degradation process in eukaryotes, which is essential for cellular homeostasis in response to various environmental and cellular stresses. During autophagy, a double-membrane structure, termed as phagophore (or isolation membrane) engulfs the cytosolic components and closes to form an autophagosome, which subsequently fuses with a lysosome, resulting in degradation of internal contents ([@bib25]). Autophagosome formation is the key process in autophagy. The biogenesis of autophagosomes is believed to be dependent on the formation of lipidated Atg8. Microtubule-associated protein light chain 3 (LC3) and GABARAP family proteins are the orthologs of yeast Atg8 in mammalian cells. Lipidated and membrane-associated Atg8/LC3 has been used as a bona fide marker of autophagosomes and progression of autophagy ([@bib10]; [@bib38]). Production of lipidated Atg8/LC3 is controlled by two ubiquitin-like conjugation systems. Newly synthesized Atg8/LC3 is processed by a protease, Atg4, to expose a C-terminal glycine. The resulting Atg8/LC3 is conjugated to phosphatidylethanolamine (PE) through a ubiquitin-like conjugation reaction controlled by Atg7, Atg3 and the Atg12-Atg5:Atg16 complex. The Atg12-5:16 complex is generated by another ubiquitin-like conjugation system controlled by Atg7 and Atg10. Atg4 releases lipidated Atg8/LC3 from the surface of autophagosomes ([@bib18]; [@bib19]; [@bib39]; [@bib46]). However, the role of Atg8-PE and its regulators in autophagosome formation remain poorly understood.

Autophagy also serves as a defense mechanism against invading pathogens (termed xenophagy) ([@bib8]; [@bib24]). Xenophagy recognizes bacteria through autophagy receptors that contain two crucial domains, the ubiquitin-binding domain (UBD) and LC3-interacting region (LIR) motifs, which are important for cargo recognition and interaction with the LC3 proteins, respectively. The receptor binds to the ubiquitinated pathogen through its UBD and recruits it to the autophagosome membrane via the interaction of the LIR motifs to LC3 proteins ([@bib20]; [@bib22]; [@bib27]; [@bib40]; [@bib43]; [@bib45]). LIR motifs are also present in receptor and scaffold proteins involved in other selective autophagy processes and play an essential role in recruiting components of the autophagy machinery to phagophores ([@bib21]; [@bib29]). However, it is not clear how LIR motifs selectively recognize mammalian Atg8 family members.

Some bacteria have evolved specific mechanisms to avoid autophagy or even hijack the autophagy machinery in order to survive in the cell ([@bib6]). The pathogenic bacterium *Legionella pneumophila*, which causes Legionnaire's disease, manipulates the core machinery of autophagosome formation to evade host autophagy. *L. pneumophila* inhibits autophagy by injecting an effector protein called RavZ into the cytoplasm. RavZ functions as a cysteine protease and irreversibly deconjugates mammalian Atg8s from PE to inhibit autophagosome formation ([@bib5]). Unlike Atg4 that cleaves the amide bond between terminal glycine and PE, RavZ cleaves the amide bond before glycine. As a consequence, the RavZ-cleaved Atg8 proteins cannot be relipidated, leading to inhibition of autophagy. RavZ represents an interesting pathogenic effector, functional characterization of which will shed light on the mechanism of autophagosome biogenesis.

To date, how RavZ recognizes and deconjugates LC3-PE is not known. This is largely due to the previously insurmountable difficulties in recombinant preparation and handling of lipidated LC3 proteins. Herein, semi-synthetic LC3 proteins make it possible to elaborate the mechanism of RavZ function. We have used chemical methods to produce LC3 proteins with different C-terminal modifications, enabling the analysis of structure-function relationships of LC3-deconjugation by RavZ, allowing formulation of a membrane extraction model. We find that RavZ extracts LC3-PE from membranes and then deconjugates C-terminal Gly-PE. We show that the second N-terminal LIR motif (LIR2) is required for RavZ activity and RavZ:LC3 interaction. The crystal structures of RavZ:LC3 and LIR2:LC3 complexes and interaction analysis suggest RavZ initially recognizes LC3 mainly via its LIR2 motif. We identify the lipid-binding site (LBS) of RavZ, which shows a similar fold to that of the LBS of yeast phospholipid transfer proteins (Sec14 family). The LBS involves a highly dynamic and hydrophobic helix α3 that is engaged in association with the membrane and plays an essential role in extraction of the conjugated PE from the membrane. Therefore, by a combination of chemical, biophysical and cell biological approaches, we gain insights into a novel mode of host-pathogen interaction.

Results {#s2}
=======

Semi-synthesis of LC3 proteins with various C-terminal modifications {#s2-1}
--------------------------------------------------------------------

Advances in protein ligation methods have provided a powerful tool for studying post-translational modified proteins ([@bib7]; [@bib11]; [@bib42]). In order to address the mechanism of *Legionella* effector RavZ function in host autophagy, we sought to produce LC3 proteins with various C-terminal modifications by expressed protein ligation (EPL) and direct aminolysis of protein thioesters ([Figure 1](#fig1){ref-type="fig"}). Previously, we reported the semi-synthesis of lipidated protein LC3-PE using a combination of lipidated peptide synthesis and EPL ([@bib47]). An MBP-assisted solubilization strategy was used to facilitate ligation under folding conditions and to solubilize the lipidated protein without detergents and membranes.10.7554/eLife.23905.003Figure 1.Semisynthesis of LC3 proteins with various C-terminal modifications.(**A**) Strategy for the semisynthesis of lipidated LC3 proteins using expressed protein ligation (EPL). (**B**) Strategy for the semisynthesis of LC3 proteins containing soluble fragments of PE by direct aminolysis.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.003](10.7554/eLife.23905.003)10.7554/eLife.23905.004Figure 1---figure supplement 1.Synthesis of peptides and PE fragments.(**A**) Synthesis of C-terminal lipidated peptides of LC3. (**B**) Chemical synthesis of compounds 8 and 10.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.004](10.7554/eLife.23905.004)

The C-terminal peptides containing DPPE (16:0) (1,2-dipalmitoyl-*sn*-glycero-3-phosphoethanolamine), DHPE (6:0) (1,2-dihexanoyl-*sn*-glycero-3-phosphoethanolamine) and 1-hexadecanol (C16) were ligated with MBP-LC3^1--114^-thioester ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). Direct aminolysis strategy ([@bib30]; [@bib48]) was used to produce LC3 proteins with modification of the soluble PE fragments, including ethanolamine (EA, **1**), phosphoethanolamine (pEA, **2**), glycerophosphoethanolamine (GpEA, **8**) and diacetyl glycerophosphoenthanolamine (DAGpEA, **10**) ([Figure 1](#fig1){ref-type="fig"}; [Supplementary file 2](#SD2-data){ref-type="supplementary-material"} and [Supplementary file 3](#SD3-data){ref-type="supplementary-material"}).

Structure-function relationship study of LC3-deconjugation by RavZ {#s2-2}
------------------------------------------------------------------

First of all, we examined whether RavZ can act on semisynthetic LC3-PE. RavZ only cleaved LC3-PE but not pro-LC3, whereas Atg4 cleaved both substrates ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In keeping with previous studies, Atg4B treatment led to LC3^1--120^, whereas RavZ-mediated deconjugation resulted in LC3^1--119^ ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In a previous report, RavZ deconjugated LC3-PE from membranes ([@bib5]). However, our results suggest that RavZ can cleave LC3-PE without the requirement for membranes.

The question then arises as to how RavZ recognizes LC3-PE. Based on the results shown above, two possible hypotheses could be made. First, RavZ would recognize a certain soluble fragment derived from the PE rather than the lipid chain, which could not be 'seen' by RavZ when it is buried in the membrane ([Figure 2A](#fig2){ref-type="fig"}). Second, the fatty acid chain would be required for binding to RavZ. In this case, LC3-PE would have to be extracted from the membrane by RavZ before proteolytic cleavage could occur. To distinguish these scenarios, a structure-function relationship study of RavZ-mediated deconjugation is required ([Figure 2B](#fig2){ref-type="fig"}). The semisynthetic LC3 proteins make it possible to perform such an analysis. LC3 proteins with different C-terminal modifications were subjected to RavZ and Atg4B treatment. The measurements showed that RavZ cannot cleave LC3 proteins containing soluble fragments derived from PE, while Atg4B is active toward these proteins ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). RavZ only cleaves PE-modified LC3 proteins, with a preference for long fatty acid chain. Enzyme kinetic data show that the catalytic efficiency of RavZ for LC3-PE (16:0) (*k~ca~*~t~/*K~m~* = 1140 M^−1^·s^−1^) is 12 times higher than that for LC3-PE (6:0) (*k~ca~*~t~/*K~m~* = 93.8 M^−1^·s^−1^) ([Figure 2B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2B--D](#fig2s2){ref-type="fig"}). LC3-C16 cannot be processed by RavZ, suggesting that LC3 with a single fatty acid chain is not sufficient for hydrolysis by RavZ ([Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}). In contrast, Atg4B can cleave all modified LC3 proteins tested ([Figure 2C](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2A and E](#fig2s2){ref-type="fig"}). Taken together, in contrast to Atg4B activity that does not require any specific structure downstream of the C-terminal glycine, RavZ activity is strictly dependent on conjugated PE structures. Therefore, it is conceivable that RavZ contains a lipid-binding site and can extract LC3-PE from the membrane before cleavage. This extraction model is further confirmed in later experiments.10.7554/eLife.23905.005Figure 2.Structure-function relationship of LC3-deconjugation by RavZ.(**A**) Schematic diagram of proteo-membrane containing LC3-PE. The fatty acid chains of PE are buried in the lipid bilayer, serving as the membrane anchor. (**B**) LC3 proteins containing different fragments derived from the PE. Ethanolamine, EA; phosphoethanolamine, pEA; glycerophosphoethanolamine, GpEA and diacetyl glycerophosphoenthanolamine, DAGpEA. (**C**) In vitro cleavage of semisynthetic LC3 proteins by Atg4B and RavZ.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.005](10.7554/eLife.23905.005)10.7554/eLife.23905.006Figure 2---figure supplement 1.In vitro cleavage of LC3 proteins with various C-terminal modifications.(**A**) In vitro LC3 cleavage assay by SDS-PAGE. RavZ only cleaves LC3-PE but not pro-LC3, while Atg4B processes both of them. (**B**) RavZ and Atg4 deconjugate LC3-PE at different sites. ESI-MS spectra of MBP-LC3-PE before and after Atg4B and RavZ treatments were shown. MBP-LC3-PE, Mw calculated 60078, found 60075; MBP-LC3^1--120^, Mw calculated 59391, found 59402; MBP-LC3^1--119^, Mw calculated 59344, found 59344. (**C**) The C-terminal lipidated peptide of LC3-PE is insufficient for RavZ proteolysis. The C-terminal lipidated peptide of LC3-PE and chimeric PE-modified Rab7 were subjected to RavZ treatment. The lipidated peptides were solved in the HEPES buffer containing detergent (30 mM HEPES 7.4, 50 mM NaCl, 2 mM DTT, 0.1% Triton X-100). RavZ (2 µM) was added to the peptide solution (2 µM) and chimeric PE-modified Rab7 (7 µM). After overnight incubation at 37°C, the reactions were subjected to LC-MS. No cleavage products were observed in these conditions. Right panel shows ESI-MS spectra of EGFP-Rab7 thioester, EGFP-Rab7-PE chimeric protein and RavZ-treated EGFP-Rab7-PE. Chimeric EGFP-Rab7-PE protein, Mw calculated 50500, found 50485.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.006](10.7554/eLife.23905.006)10.7554/eLife.23905.007Figure 2---figure supplement 2.Structure-function relationship study of LC3-deconjugation by RavZ.(**A**) ESI-MS spectra of modified LC3 (S1--S4) before (black line) and after Atg4B (red line) or RavZ treatment (blue line). 0.7 µM LC3 proteins were incubated with 0.7 µM Atg4B or RavZ for 8 hr at 37°C. (**B**) Kinetics of RavZ-medicated cleavage reactions with LC3-PE (16:0) and LC3-PE (6:0) (S5). 7 µM LC3-PE (16:0) or LC3-PE (6:0) was incubated with RavZ (0.7 µM) at 37°C. The reaction was quenched at different time points and subjected to SDS-PAGE. The graphs in the lower panel show reaction progress. The red solid line shows the fitting to a single-exponential equation to obtain t~1/2~. (**C**) Enzyme kinetics of RavZ reaction. Varying concentrations of LC3-PE (16:0) or LC3-PE (6:0) were incubated with RavZ (0.7 µM) for 8 min or for 140 min at 37°C, respectively. The reaction was quenched and subjected to SDS-PAGE. In the lower panel, the reaction rates were plotted against substrate concentrations. The red solid line shows the fitting to Michaelis-Menten equation. (**D**) Summary of Michaelis-Menten kinetic parameters. n = 3 independent experiments. Mean and SD are presented. (**E**) In vitro cleavage assay of LC3-C16 (S6). LC3-C16 was treated with Atg4B or RavZ (0.7 µM) at 37°C for 2 hr and subjected to SDS-PAGE. (**F**) Kinetics of RavZ^20-331^-medicated cleavage reaction with LC3-PE (16:0). The same conditions were used as in (**B**). (**G**) The exponential decay curve showing the half-time (t~1/2~) of LC3-PE cleavage activity of RavZ^20-331^. n = 3 independent experiments. Mean and SD are presented.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.007](10.7554/eLife.23905.007)

Interestingly, RavZ did not process PE-peptides containing 6, 7 or 11 C-terminal amino acid residues. To further confirm the findings, we ligated the CQETFG-PE peptide to the C-terminus of Rab7 GTPase. Again, RavZ cannot hydrolyze the chimeric Rab7-PE protein ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). These results suggest that a C-terminal PE-modified peptide is not sufficient for substrate recognition and cleavage by RavZ.

RavZ extracts LC3-PE from membranes {#s2-3}
-----------------------------------

The structure-function relationship studies prompted us to examine the extraction model of RavZ. To this end, we used protease-deficient RavZ^C258A^ in an LC3-PE extraction assay ([Figure 3A](#fig3){ref-type="fig"}). MCF-7 cells stably expressing GFP-LC3 were subjected to starvation to induce autophagy. The membrane fraction of cells was incubated with different concentrations of RavZ^C258A^ protein. The supernatant was precipitated using TCA/DOC (trichloroacetic acid/sodium deoxycholate). The soluble proteins in supernatant and the membrane-associated proteins were visualized by immunoblotting with anti-LC3 antibody. Our results showed that RavZ^C258A^ treatment decreased the level of membrane association of both endogenous LC3-II (lipidated LC3) and GFP-LC3-II in a dose-dependent manner. Accordingly, the level of soluble LC3-II and GFP-LC3-II increased with increasing concentration of RavZ^C258A^. These results suggest that RavZ^C258A^ extracts lipidated LC3 from membranes.10.7554/eLife.23905.008Figure 3.RavZ extracts LC3-PE from membranes.(**A**) LC3-PE extraction assay. Endogenous LC3-PE and GFP-LC3-PE on membranes from GFP-LC3 stable cells (20 µg) were treated with increasing concentrations of recombinant RavZ^C258A^. After incubation for 2 hr at 37°C, the membrane and soluble fractions were separated by ultracentrifuge and subjected to western blotting with LC3-specific antibody. Upper panel shows the schematic diagram of LC3-PE extraction by RavZ^C258A^. (**B**) Confocal microscopy of GFP-LC3 stable cells transfected with mCherry-RavZ constructs. Cells were treated for 2 hr under starvation medium (EBSS). A complete set of images for GFP-LC3 cells transfected with all mCherry-RabZ constructs (WT, C258A, and their mutants) are shown in [Figure 6---figure supplement 2A and B](#fig6s2){ref-type="fig"}. (**C**) Quantification of GFP-LC3 puncta shown in (**B**). n = 21--32 cells. Mean and SD are presented; \*\*\*p\<0.001, \*p\<0.05. (**D**) Effect of RavZ on LC3-II level in cells. GFP-LC3 stable cells were transfected with wild-type RavZ (WT) and RavZ^C258A^ and cultured either in growth or in starvation medium. (**E--G**) Quantification of ratio of endogenous LC3-II to LC3-I (**E**), GFP-LC3-II to GFP-LC3-I (**F**) and p62 to actin (**G**) in (**D**). n = 3 independent experiments. Mean and SD are presented; \*\*\*p\<0.001, \*p\<0.05, ns: not significant. (**H**) Validation of LC3-PE extraction by RavZ in the cell. GFP-LC3 stable cells were transfected with RavZ^C258A^. After starvation, cells were lysed. Membrane fractionation was performed by ultracentrifuge. The membrane and soluble fractions were subjected to western blotting.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.008](10.7554/eLife.23905.008)10.7554/eLife.23905.009Figure 3---figure supplement 1.Membrane binding and α3 are required for extraction activity of RavZ.(**A**) Confocal microscopy of HeLa cells co-transfected with GFP-LC3 and mCherry-RavZ constructs after starvation for 2 hr in EBSS. (**B**) Quantification of GFP-LC3 puncta in (**A**). n = 25--30 cells. Mean and SD are presented; \*\*\*p\<0.001, ns: not significant. (**C**) GFP-LC3 expression levels in stable and transient cells by western blot. (**D**) Fluorescence microscopy of GFP-LC3 transiently transfected cells. The percentage of transfection efficiency = (number of cells stained with fluorescent/total number of cells per field) X 100. (**E**) Quantification of the ratio of transient and stable GFP-LC3 expression level to actin in (**C**). n = 3. Mean and SD are presented. (**F**) LC3-PE extraction assay. GFP-LC3-PE on membranes from GFP-LC3 stable cells (20 µg) was treated with increasing concentrations of recombinant RavZ^C258A^, α3-m3 (C258A) mutant or 1-331(C258A) fragment. After incubation for 2 hr at 37°C, the membrane and soluble fractions were separated by ultracentrifuge and subjected to Western blotting with LC3-specific antibody. (**G**) Quantification of the LC3-II level in membrane and supernatant fractions in (**F**). n = 3 independent experiments. Mean and SD are presented.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.009](10.7554/eLife.23905.009)

To further evaluate the extraction activity of RavZ in vivo, GFP-LC3 stable cells were transfected with mCherry, mCherry-RavZ wt or mCherry-RavZ^C258A^. Both RavZ wt and RavZ^C258A^ significantly inhibited GFP-LC3 puncta formation ([Figure 3B and C](#fig3){ref-type="fig"}). However, the inhibitory effect of RavZ^C258A^ was not observed in a previous report, where GFP-LC3 and RavZ^C258A^ were transiently expressed in the cell ([@bib5]). We repeated the experiment using cells transiently expressing GFP-LC3. We also find that RavZ wt but not RavZ^C258A^ inhibits GFP-LC3 puncta formation under these conditions, probably due to the high expression level of GFP-LC3 in transient cells ([Figure 3---figure supplement 1A--1E](#fig3s1){ref-type="fig"}). RavZ wt but not RavZ^C258A^ led to decrease in LC3-II level in GFP-LC3 cells ([Figure 3D--3F](#fig3){ref-type="fig"}). Moreover, lipidated LC3 was found in the soluble fraction in RavZ^C258A^-expressing cells, which is in contrast to the control, where lipidated LC3 is only found in the membrane fraction ([Figure 3H](#fig3){ref-type="fig"}). Both RavZ wt and RavZ^C258A^ significantly inhibited p62 degradation, a marker for autophagy flux ([Figure 3D and G](#fig3){ref-type="fig"}). Therefore, the inhibitory effect of RavZ^C258A^ is a result of extraction of lipidated LC3 molecules from membranes, leading to accumulation of LC3-II in the cytosol and reduction of membrane-localized LC3 proteins. This scenario is quite different from the effect of overexpression of Atg4B^C74A^ (a protease-deficient mutant), which inhibits LC3 lipidation by sequestration of unlipidated LC3 through formation of stable complexes in the cytosol ([@bib10]). Since the lipidated LC3 level is not changed in RavZ^C258A^-expressing cells, RavZ^C258A^ inhibits autophagy by sequestrating lipidated LC3 proteins rather than unlipidated LC3 proteins. These findings indicate that RavZ does not interfere with autophagy machinery upstream of Atg8/LC3 but specifically processes lipidated LC3 proteins.

The LIR motif is essential for RavZ activity {#s2-4}
--------------------------------------------

The importance of the LIR motif for recognition of Atg8/LC3 in selective autophagy prompted us to identify LIR motifs in RavZ. The LIR motif is composed of conserved W/Y/FxxL/I/V sequence. The binding of LIR motifs with Atg8/LC3 proteins is quite conserved, with two key hydrophobic residues playing an essential role in interaction with the hydrophobic pocket of the Atg8s ([@bib13]; [@bib28], [@bib29]). Three potential LIR motifs of RavZ were identified by the iLIR online server ([@bib17]) ([Figure 4A](#fig4){ref-type="fig"}). The first and second LIR motifs are located at the N-terminal region of RavZ (residues 14--19, LIR1; and 27--32, LIR2), while the third motif is in the C-terminal region (residues 433--438, LIR3). To identify which LIR motif is involved in RavZ activity and to map the catalytic domain of RavZ, RavZ was dissected into fragments and subjected to the in vitro LC3-PE cleavage assay and to measurement of binding with LC3 by a fluorescence polarization assay ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Truncation of LIR1 (20--502) and LIR3 (1--431) did not influence RavZ activity and led to only up to ca. twofold reduction of binding affinity with LC3, whereas simultaneous truncation of LIR1 and LIR2 (33--502 and 55--487) completely abolished cleavage activity and reduced the binding affinity with LC3 by 2--4 fold ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). Mutation of the key aromatic residue (F29A) of LIR2 led to dramatic reduction of RavZ activity, whereas mutation of LIR1 (F16A) did not affect RavZ activity. The RavZ^F16/F29A^ mutant showed the same effect as RavZ^F29A^ ([Figure 4C and D](#fig4){ref-type="fig"}). These results demonstrate that LIR2 is crucial for RavZ activity. However, fragments containing one of the LIR motifs can still form stable complexes with LC3. In contrast, RavZ fragments (55--430 and 55--331) without LIR motifs completely lost their binding ability to LC3 ([Figure 4A](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1A and B](#fig4s1){ref-type="fig"}). Therefore, LIR2 is crucial for both binding and cleavage activities. Indeed, RavZ fragment 20--331 that contains only LIR2 can cleave LC3-PE with only twofold decrease in binding affinity to LC3. Thus, RavZ^20-331^ represents the minimal catalytic domain. Prompted by these results, we tested binding of the LIR2 peptide (DIDEFDLLEGDE) to LC3 by ITC and binding of the fluorescein-labeled LIR2 peptide to LC3 by fluorescence polarization, leading to dissociation constants (K~d~) of 360 nM and 550 nM, respectively, which is comparable with that of RavZ:LC3 complex (K~d~ = 260 nM) ([Figure 4---figure supplement 1C and D](#fig4s1){ref-type="fig"}). Therefore, the LIR2 motif of RavZ contributes the major binding energy for RavZ:LC3 interaction.10.7554/eLife.23905.010Figure 4.The LIR motif is essential for RavZ:LC3 binding and cleavage activity of RavZ.(**A**) Schematic diagram of RavZ fragments showing LIR motifs and the catalytic residue Cys258. Binding and cleavage activities of the fragments are shown. (**B**) In vitro LC3-PE cleavage assay of the RavZ fragments. (**C**) In vitro LC3-PE cleavage assay of RavZ containing LIR mutations. The LC3-PE protein (7 µM) was treated with RavZ mutants (700 nM) at 37°C for 10 min or 20 min and then resolved by SDS-PAGE. (**D**) Quantification of the LC3-PE cleavage in (**C**). n = 3 independent experiments. Mean and SD are presented; \*\*p\<0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.010](10.7554/eLife.23905.010)10.7554/eLife.23905.011Figure 4---figure supplement 1.LIR2 is required for RavZ:LC3 interaction.(**A**) Gel filtration analysis of complex formation of LC3^1--119^ with RavZ^1--502^ or RavZ^55-430^. Orange line indicates elution profile of the mixture of RavZ and LC3, blue and green lines indicate profiles of RavZ and LC3 alone, respectively. Gray dashed line indicates elution profile of protein markers (from left to right): 670, 158, 44, 17 and 1.3 kDa. The black line underneath the profile indicates collected fractions for SDS-PAGE analysis shown below. (**B**) Interaction analysis of RavZ fragments with LC3^1--119^ by fluorescence polarization. Dissociation constants are shown in the table (right). (**C**) Interaction analysis of the FITC-LIR2 peptide with LC3 by fluorescence polarization. Dissociation constants are shown in the table (right). (**D**) Interaction analysis of LIR2 with LC3 using ITC technique. Upper panel is thermographic binding isotherm and lower panel is the fit of the binding. \* The K~d~ was obtained from three independent ITC experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.011](10.7554/eLife.23905.011)

RavZ membrane binding is required for extraction {#s2-5}
------------------------------------------------

Next, we solved the structures of two RavZ fragments, 1--487 and 20--502. Crystal structures of the fragments are essentially identical, solved in space group I422. RavZ structures of both fragments are resolved from residues 47 to 433 and 48 to 432, respectively, whereas the missing regions at the N- and C-termini (residues 1--47 and 433--502) might be flexible and disordered. Our RavZ structures are identical to the reported RavZ structure (PDB:5CQC) with an RMSD of 0.33 ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}) ([@bib12]). RavZ shows two major domains, the N-terminal catalytic domain (residues 49--320, catalytic triad: C258, H176, D197) and the C-terminal domain (329-423). In line with the crystal structure, RavZ^1--331^ showed similar LC3-binding affinity and catalytic efficiency to the wild-type RavZ ([Figure 4A](#fig4){ref-type="fig"}; [Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"}, [Figure 2---figure supplement 2G](#fig2s2){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}), suggesting the catalytic domain is sufficient for deconjugation of LC3-PE. The C-terminal domain has been recently shown to be involved in association with phosphatidylinositol 3-phsphate (PI3P) and be essential for membrane binding ([@bib12]). Interestingly, although the catalytic domain is sufficient for cleavage, the extraction activity is reduced ([Figure 3---figure supplement 1F and G](#fig3s1){ref-type="fig"}). Since the catalytic domain does not bind to membranes ([@bib12]), membrane binding of RavZ is required for extraction of LC3-PE in vivo.

Structural analysis of RavZ:LC3 interaction {#s2-6}
-------------------------------------------

To understand how RavZ recognizes LC3 before extraction, we solved the crystal structure of the RavZ^1--431^:LC3^1--119^ complex at 2.5 Å ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). The complex shows 1:1 stoichiometry. However, the complex displays only a relatively small binding interface (300 Å^2^). Nevertheless, the structure of RavZ in the complex shows a well-defined resolution of flexible loops, which are missing in the free-structure. The loop (249--253), loop (278--287) and the α8-α9 loop (346--356) are now visible ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}). Importantly, the N-terminal loop containing the LIR2 motif (residues 25 to 48) is resolved in the structure. LIR2 of RavZ interacts with the α2-β3 loop of LC3 instead of the canonic LIR-binding site that involves hydrophobic pockets located in β1, β2 and α3 ([@bib28], [@bib29]). Further analysis of the crystal contacts between symmetry-related RavZ molecules (RavZa and RavZb) shows that LIR2 of RavZa interacts extensively with RavZb, involving the α3 loop and the β6-β7 loop ([Figure 5A](#fig5){ref-type="fig"}). Comparing with the free-RavZ structure, the α3 loop in the complex moves ca. 9 Å inward, suggesting a dynamic nature of this region ([Figure 5B](#fig5){ref-type="fig"}). Key hydrophobic interactions include F29 (RavZa) with Y211 (RavZb), L31 (RavZa) with I170 (RavZb), L208 (RavZb) and F212 (RavZb). It is conceivable that the crystal packing led to a low-energy binding configuration involving interaction of LIR2 with the α3 loop of its symmetric mate. Such an interaction is less likely to exist outside the crystal, because the affinities of the α3 mutant (Y211D/F212D/Y216D) and the wild-type RavZ toward LC3 are identical ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}). The result indicates that there is no defined LC3-binding site on RavZ except for the LIR2 loop.10.7554/eLife.23905.012Figure 5.Structural basis of RavZ:LC3 interaction.(**A**) Crystal structure of the RavZ:LC3 complex. Catalytic domain, the PIP3-binding domain and the N-terminal loop containing LIR2 of RavZa are shown in blue, teal and pink, respectively. The LC3 molecule is shown in green with its α2 and the α2--β3 loop colored in orange. The symmetry-related RavZ (RavZb) molecule is shown in pale cyan with its α3 and the the β6--β7 loop colored in yellow. (**B**) Binding interface between LC3 with RavZa and RavZb. Free RavZ structure (gray) is superimposed with RavZb to show the conformational change of α3. Hydrogen bonds are shown as red dashed lines. (**C**) Crystal structure of the LIR2:LC3 complex. LC3 is colored in green and the LIR2 peptide is coloured in pink. Hydrogen bonds are shown as red dashed lines. (**D**) Interaction of LIR2 with LC3. LIR peptide is shown as pink stick and LC3 is displayed as surface. Two hydrophobic binding pockets (HP1 and HP2) are shown in pale yellow. The 2Fo--Fc map of the LIR2 motif is contoured density at α of 1.0.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.012](10.7554/eLife.23905.012)10.7554/eLife.23905.013Figure 5---figure supplement 1.LIR2 is required for RavZ:LC3 interaction.(**A**) Interaction analysis of the FITC-LIR2 peptide with LC3, GABARAPL1 and GATE16 by fluorescence polarization. Dissociation constants are shown in the table (below). (**B**) Inhibition of RavZ activity by the LIR2 peptide. The LC3-PE protein (7 µM) was incubated with different concentrations of LIR2 peptide for 1 hr on ice and was subjected to RavZ (0.7 µM) treatment for 10 min at 37°C. The reaction was resolved by SDS-PAGE. The data were fitted to a sigmoidal equation, leading to IC~50~ value. n = 3 independent experiments. Mean and SD are presented. (**C**) Competitive titration assay by fluorescence polarization measurement. 1.25 µM FITC-LIR2 was titrated with 6.25 µM LC3 and then with increasing concentrations of RavZ. Full recovery of fluorescence polarization signal for FITC-LIR2 was observed (orange columns). In the control experiment, LC3 was omitted (green unfilled columns). No binding between FITC-LIR2 and RavZ was observed.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.013](10.7554/eLife.23905.013)10.7554/eLife.23905.014Figure 5---figure supplement 2.Structural analysis of free RavZ and RavZ:LC3 complex.(**A**) Structural comparison of free RavZ with the published RavZ (PDB: 5CQC). Catalytic domain and PI3P-binding domain of our RavZ structures are colored in blue and deep-teal, respectively. Published RavZ structure is colored in gray, α3 hydrophobic residues and PI3P binding residues are shown as stick models and colored in orange and magenta, respectively. (**B**) Structural comparison of free RavZ(deep-teal), RavZ in complex with LC3 (pale cyan) and published RavZ (gray). The missing loops in the published RavZ that are found in our free RavZ and complexed RavZ are colored in orange and red, respectively. (**C**) Structural comparison of the docking structure of RavZ:LC3 complex and the crystal structure of Atg4B:LC3. RavZ is shown in deep-teal, Atg4B is shown in light pink, LC3^RavZ^ is shown in green and LC3^Atg4B^ is shown in light orange. N-terminal LIR2^RavZ^ and N-terminal LIR^ATG4B^ are indicated in red and blue, respectively. The catalytic triad is shown as a stick model. (**D**) Crystal packing of the LIR2-fused LC3 protein. LC3 molecules in chain A and chain B are shown in green and cyan, respectively. LIR2 is colored in magenta. Black dashed line indicates asymmetric unit.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.014](10.7554/eLife.23905.014)

To prove whether LIR2 interacts with the LIR-binding site in LC3, we solved two structures of an LIR2-LC3 fusion in two crystallization conditions. Both structures are identical and solved in the same space group ([Supplementary file 4](#SD4-data){ref-type="supplementary-material"}). There are two molecules (molecule A and B) of the LIR2-LC3 fusion in one asymmetric unit with LIR2 of each molecule interacting with its symmetry-related LC3 molecule ([Figure 5---figure supplement 2D](#fig5s2){ref-type="fig"}). The hydrophobic interaction of LIR2 with LC3 is conserved and adopts the classical LIR-LC3-binding mode ([@bib21]; [@bib29]). The first aromatic residue, F29, of LIR2 interacts with the first hydrophobic pocket (HP1) consisting of I23, P32, L53, F108 and the alkyl sidechain of K51 and the second aromatic residue L32 interacts with the second hydrophobic pocket (HP2) consisting of F52, V54, P55, V58, L63 and I66 ([Figure 5C and D](#fig5){ref-type="fig"}). The salt bridge interactions of residues LIR2^E28^ with LC3^K51^ and LIR2^D30^ with LC3^R70^ are observed in both structures. We further investigate whether RavZ shows preference on binding to individual Atg8 family proteins, we tested binding of LIR2 peptide with three Atg8 members (representing two subfamilies), LC3B, GABARAPL1 and GATE16. No significant difference in binding affinities was observed ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Therefore, RavZ has no preference in binding to Atg8 proteins.

To verify the interaction of LIR2 with LC3 seen in the crystal structure, we mutated the interacting residues on LC3, hydrophobic residues (F52 and L53) and charged residues (K51 and R70), to alanine. The mutants were subjected to binding analysis with the LIR2 peptide by fluorescence polarization. F52A mutation led to the reduction of LIR2 binding by about sixfold (K~d~ = 3.14 µM), while R70A mutation reduced binding affinity about 15-fold (K~d~ = 8.10 µM). L53A and K51A mutation led to only residual effect on binding to LIR2. No binding of the free LIR2 peptide with the LIR2-LC3 fusion protein was observed under these conditions, suggesting that the LIR2 peptide competes with the conjugated LIR2 peptide for binding to the LIR-binding site of LC3 ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). Moreover, RavZ and the LIR2 peptide bind to LC3 in a competitive manner, as shown by the competitive titration and enzymatic inhibition assay ([Figure 5---figure supplement 1B and C](#fig5s1){ref-type="fig"}). Therefore, RavZ recognizes LC3 mainly via its N-terminal LIR2 motif by binding to the LIR-binding site in LC3.

Molecular basis of LC3-PE extraction by RavZ {#s2-7}
--------------------------------------------

In order to understand the thermodynamic basis of RavZ extraction, we sought to determine the binding affinity of RavZ^C258A^ with LC3-PE and LC3^1--119^ by microscale thermophoresis (MST) technique. To make LC3-PE soluble in solution without detergent, MBP tag was left intact. The measurements showed that RavZ^C258A^binds to MBP-LC3-PE and MBP-LC3^1--119^ with dissociation constants (Kd) of 23 ± 4 nM and 69 ± 5 nM, respectively, which suggests that RavZ binds to lipidated LC3 in three times higher affinity than unlipidated LC3 ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Therefore, the thermodynamic driving force for RavZ extraction is modest but still favorable.

Based on our model, there should be a lipid-binding site (LBS) in RavZ. The amino acid sequence of RavZ does not give any hint of the LBS. We superimposed the free RavZ structure with the phospholipid-binding domain of Sec14 proteins (PDB: 1AUA and 3B74), which are the major yeast phosphatidylinositol (PtdIns)/phosphatidylcholine (PtdCho) transfer proteins and are essential for lipid metabolism ([@bib34]; [@bib44]). Structural alignment indicated that part of the N-terminal catalytic domain of RavZ (α2--α4, β6--β9) shows a similar fold to that of the core-lipid-binding domain of Sec14, consisting of 5 β-strands and 4 α-helices (α7--α10) ([@bib34]) ([Figure 6A](#fig6){ref-type="fig"}). The β sheets of Sec14 serve as the floor of hydrophobic binding pocket, along helices α7-α10 that gate the Sec14 pocket, forming extensive van der Waals contacts with the bound fatty acid chains. Helices α9--α10 act as lid helices, which move toward helix α8 upon lipid binding to form a closed conformation to capture lipid into the binding site ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"}) ([@bib44]). Similarly in RavZ, helices α2 (corresponding to α7 of Sec14) and α4 (corresponding to α8 of Sec14) along β sheets form a large hydrophobic interface ([Figure 6A and B](#fig6){ref-type="fig"}). However, the hydrophobic pocket is closed in RavZ, suggesting that a conformational change may be required to accommodate the fatty acid chains. A lid helix in RavZ is not clearly observed based on the structural alignment. However, due to the highly dynamic and hydrophobic nature of α3, it is possible that α3 may resemble the function of the lid helix and may undergo substantial movements to interact and stabilize the lipid moiety in the LBS upon binding of PE.10.7554/eLife.23905.015Figure 6.Identification of the lipid-binding site (LBS) of RavZ.(**A**) Structural alignment between the lipid-binding sites of yeast Sec14 homolog (Shf1) (PDB: 3B74) and RavZ. RavZ is colored in pale yellow, while Shf1 is shown as a green transparent cartoon and its secondary elements are indicated. The phosphatidylethanolamine (PE) is shown as stick model with carbon atoms colored in magenta. (**B**) Structure of N-terminal catalytic domain of RavZ showing the LBS of RavZ and the predicted lipid-binding residues. The α3 loop and α4 are colored in orange and light pink, respectively. The residues involved in lipid binding are highlighted and displayed as side chain sticks. (**C**) In vitro LC3-PE cleavage assay of RavZ mutants. (**D**) Effect of RavZ mutants on LC3-II level in the cell. GFP-LC3 stable cells were transfected with RavZ mutants and subjected for starvation for 2 hr. (**E**) Quantification of the ratio of endogenous LC3-II to LC3-I (left) and GFP-LC3-II to GFP-LC3-I (right) shown in (**D**). n = 3 independent experiments. Mean and SD are presented; \*\*\*p\<0.001, \*\*p\<0.01, ns: not significant. (**F**) Effect of RavZ mutants on GFP-LC3 puncta formation in the cell as shown in [Figure 6[---]{.ul}figure supplement 2A](#fig6s2){ref-type="fig"}. n = 25--37 cells. Mean and SD are presented; \*\*\*p\<0.001, \*\*p\<0.01, ns: not significant. (**G**) Effect of RavZ^C258A^ mutants on GFP-LC3 puncta formation in the cell as shown in [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}. n = 22--35 cells. Mean and SD are presented; \*\*\*p\<0.001, \*\*p\<0.01, ns: not significant.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.015](10.7554/eLife.23905.015)10.7554/eLife.23905.016Figure 6---figure supplement 1.Structural analysis of the lipid-binding site of free RavZ, free Sec14 and PE-bound Sfh1.(**A**) Structural comparison of N-terminal catalytic domain of RavZ with NEDP1. RavZ and NEDP1 are colored in pale yellow and pale green, respectively. The α3 loop of RavZ is shown in orange. (**B**) Surface representation of LBS of free RavZ and free Sec14 (PDB: 1AUA). The lipid-binding cavity of Sec14 is observed. The PE group is shown in the cavity by alignment with the PE-bound Sfh1 (3B74). (**C**) Structural comparison of free Sec14 (PDB: 1AUA) and PE-bound Sfh1. The lid helix (α9-α10) of free Sec14 and PE-bound Sfh1 is colored in deep teal and green, respectively. (**D**) Interaction analysis of RavZ^C258A^ with MBP-LC3-PE (16:0) or MBP-LC3^1--119^ using MST technique.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.016](10.7554/eLife.23905.016)10.7554/eLife.23905.017Figure 6---figure supplement 2.Functional characterization of the lipid-binding site of RavZ.(**A**) Confocal microscopy of GFP-LC3 stable cells transfected with mCherry-RavZ constructs. Before imaging, cells were treated for 2 hr under starvation medium (EBSS). (**B**) Confocal microscopy of GFP-LC3 stable cells transfected with mCherry-RavZ C258A constructs. Before imaging, cells were treated for 2 hr under starvation media (EBSS). (**C**) Binding of RavZ LBS mutants with LC3 by fluorescence polarization. Dissociation constants are shown in the table. (**D**) Circular dichroism (CD) spectra of RavZ and its variants.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.017](10.7554/eLife.23905.017)

In order to prove the predicted LBS of RavZ, we mutated a set of hydrophobic residues on α2, α3, α4, the α4-β9 loop and β7 to the negatively change residue Asp ([Figure 6B and C](#fig6){ref-type="fig"}). The In vitro LC3-PE cleavage assay showed that most of the mutants affect the cleavage activity of RavZ. The double mutation (Y211D/F212D, α3-m2) or triple mutation (Y211D/F212D/Y216D, α3-m3) in α3 completely abolished the cleavage activity. A single mutation scan shows that F211D, Y212D and L208D dramatically reduce the cleavage activity, whereas the Y216D mutant largely retains activity. Triple mutation of the gate residues on α4 (L224D/I288D/L232D) and the α4-β9 loop (F242D/L239D/F237D) led to significant reduction in cleavage activity. To confirm the floor residues of the hydrophobic pocket of RavZ, we mutated hydrophobic residues on α2 (L139D/L143D) and β7 (L180D/I182D). Again, these mutations significantly reduced cleavage activity ([Figure 6C](#fig6){ref-type="fig"}).

To evaluate the deconjugation activity of RavZ mutants in cells, GFP-LC3 cells were transfected with different mCherry-RavZ mutant constructs. An additional mutant RavZ^F163D^ (F163 on β6 located inside of the hydrophobic cavity) was also included in the assay. The level of LC3-II was evaluated by Western blotting ([Figure 6D](#fig6){ref-type="fig"}) and GFP-LC3 puncta assay ([Figure 6F](#fig6){ref-type="fig"}). Cells expressing RavZ mutants displayed a significant increase in the ratio of endogenous LC3-II/LC3-I as well as the ratio of GFP-LC3-II/GFP-LC3-I and in the number of GFP-LC3 puncta, compared to those expressing wild-type RavZ ([Figure 6E and F](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}), suggesting that deficient activity of RavZ mutants results in decreased deconjugation of LC3-PE in cells. Moreover, the α3-m2 mutant completely abolished RavZ deconjugation activity in vivo. These results are in line with those obtained by the in vitro LC3-PE cleavage assay.

To further examine the extraction activity of RavZ mutants, GFP-LC3 cells were transfected with mCherry-RavZ^C258A^ mutant constructs. In keeping with the deconjugation results, a significantly higher number of GFP-LC3 puncta was observed in cells expressing RavZ^C258A^ mutants than those expressing RavZ^C258A^, indicating less extraction activity of these mutants in vivo ([Figure 6G](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Consistently, the α3-m2 and α3-m3 mutants completely lost extraction activity ([Figure 6G](#fig6){ref-type="fig"}; [Figure 3---figure supplement 1F and G](#fig3s1){ref-type="fig"}). Moreover, all RavZ mutants bind to LC3 with similar K~d~ values to those of the wild-type protein ([Figure 6---figure supplement 2C](#fig6s2){ref-type="fig"}) and display similar secondary structure with comparable α helix content to the wild-type protein ([Figure 6---figure supplement 2D](#fig6s2){ref-type="fig"}). Therefore, the mutations do not significantly affect protein folding and binding to LC3. Taken together, we conclude that the LBS of RavZ, consisting of α2, α3, α4, α4--β9 loop and β sheets (β6--β9), accommodates the fatty acid chains of PE. The LBS plays an essential role in extraction and cleavage of LC3-PE.

Discussion {#s3}
==========

In previous studies, the substrate LC3-PE was produced on liposomes by recombinant reconstitution of the ubiquitin-like conjugation system (i.e. mammalian Atg7, Atg3 and Atg8s) ([@bib5]). The question then arises whether RavZ activity requires membranes or not. However, production of liposome-free LC3-PE and manipulation of LC3-PE structures are difficult using the recombinant approach. In this study, the semisynthetic approach makes it possible to address these inherent problems in the analysis of post-translationally modified proteins. We have used chemical approaches to prepare LC3 proteins with various modifications in a membrane-free manner.

Using semisynthetic LC3 proteins modified with various PE fragments, we analyzed the structure-function relationship of LC3 deconjugation by RavZ. We demonstrate that RavZ activity is strictly dependent on the lipid structure of the substrate and RavZ cleaves LC3-PE without requirement for membranes. These observations indicate an extraction model of RavZ function, which is further proved by the extraction assay using protease-deficient RavZ. This is the first-time identification of such an action mode for host-pathogen interactions. Although the N-terminal catalytic domain is sufficient to bind and cleave LC3-PE in solution, its extraction activity and thereby its deconjugating activity in vivo are attenuated ([Figure 6E--G](#fig6){ref-type="fig"}; [Figure 3---figure supplement 1F and G](#fig3s1){ref-type="fig"}). Therefore, association of RavZ with membranes via its C-terminal PI3P-binding domain is also required for efficient extraction in vivo, probably by targeting RavZ to the autophagosome membrane ([@bib12]). *L. pneumophila* may have evolved both functions simultaneously, that is extraction and cleavage. The former determines the specificity and the latter confers the turnover. Without retrieval of LC3-PE from membranes RavZ cannot perform proteolytic activity. However, although extraction alone is sufficient to inhibit autophagy, it requires a much higher amount of RavZ molecules because it is driven by stoichiometric binding between RavZ and LC3-PE. The proteolytic function of RavZ drives turnover of LC3-PE molecules, so that less than stoichiometric amounts of RavZ molecules are needed. It is possible that the extraction model may be present in other host-pathogen interactions, such as *Shigella* effector IpaJ with N-myristoylated Arf GTPases and *Yersinia* effector YopT with prenylated RhoA GTPases, since these effectors also recognize the lipid group ([@bib2], [@bib3]; [@bib35], [@bib36]).

We have demonstrated that the LIR2 motif (residue 27--32) plays an essential role in RavZ activity and RavZ:LC3 interaction. Interestingly, the LIR motif at the N-terminal tail of Atg4B is involved in regulation of Atg4B activity. Binding of the LIR motif with the second non-substrate LC3 molecule leads to an open conformation, which is required for deconjugation of LC3. Atg4B lacking the N-terminal tail shows higher processing activity ([@bib33]). It is not clear whether such interaction occurs in vivo. However, the LIR2 motif of RavZ is required for initial recognition of LC3. The LIR-LC3 binding constitutes the major interaction between RavZ and LC3 before extraction of the PE moiety from the membrane. Therefore, LIR2 is involved in recognizing and orienting the LC3 molecule to facilitate subsequent extraction and cleavage of LC3-PE. According to this model, it is not surprising that RavZ does not process PE-peptides containing C-terminal amino acid residues of LC3 and the Rab7-CQETFG-PE chimeric protein, due to the lack of LIR binding. In contrast, *Shigella* effector IpaJ and *Yersinia* effector YopT can process the lipidated peptides containing an N-myristoylated glycine and a C-terminally prenylated polybasic sequence, respectively, suggesting a unique manner of recognizing substrate for RavZ ([@bib2], [@bib3]; [@bib35], [@bib36]). Based on this finding, we are able to inhibit RavZ activity by the LIR2 peptide (IC~50~ = 43 µM) ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), suggesting that suppression of LIR-LC3 binding could be beneficial for attenuating inhibition of host autophagy by *L. pneumophila*.

Through structural alignment with yeast lipid transfer proteins and mutagenesis studies, we have identified the LBS of RavZ, involving α2, α3, α4, the α4--β9 loop and β sheets (β6--β9). The LBS is required for both extraction and cleavage of LC3-PE. Therefore, LIR2:LC3 and LBS:PE interactions may constitute two major binding interfaces for RavZ:LC3-PE complex, which place the C-terminal tail of LC3 at the correct position of the active site of RavZ for cleavage. However, such a LBS is not observed in Atg4B ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}), consistent with the observation that Atg4B has no specificity toward structures C-terminal to the scissile bond. This could be one of the explanations for the distinct modes of action of Atg4 and RavZ. The fold of the N-terminal catalytic domain of RavZ is closely related to cysteine proteases in the ubiquitin-like (Ubl)-specific protease (Ulp) family that is specific for de-conjugating Ubl proteins ([@bib26]; [@bib37]). A similar LBS fold is also found in Ulp proteins (NEDP1, PBD: 2BKR), but this fold is lack of the α3 loop ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). It should be noted that the LBS of RavZ is closed without showing a binding pocket for lipid, whereas a clear hydrophobic binding cavity that can accommodate fatty acid chains is observed in free Sec14 structures ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Because the PE moiety involves interaction with residues located deep in the LBS fold, there must be a conformational change to open the lipid-binding site, for example, by outward movement of α4. Because α4 is connected to β9 *via* the highly dynamic α3 loop, such a movement could be made possible. These findings are in keeping with the important role of the α3 loop in RavZ activity ([Figure 6C--6F](#fig6){ref-type="fig"}; [Figure 3---figure supplement 1F and G](#fig3s1){ref-type="fig"}). The hydrophobic and dynamic features of α3 are in agreement with this proposed function. The association of α3 with the membrane, as shown previously ([@bib12]), may facilitate initial interaction of α3 with the conjugated PE in the membrane. Subsequently, the lipid-binding site of RavZ is open and able to accommodate the PE moiety that is dug out of the membrane by α3, which moves toward the LBS. The α3 may serve as a lid for the lipid-binding pocket to confer the binding of fatty acid chains.

Intracellular molecules with analogous feature, that is extraction of lipidated proteins, are GDP-dissociation inhibitors (GDIs) and the GDI-like molecule PDEδ, which serve as recycling factors for prenylated Ras GTPase family proteins (Ras, Rho and Rab) between membranes and the cytosol ([@bib15]; [@bib32]; [@bib41]). Interestingly, the lipid-binding site of isolated RabGDI is also closed and undergoes a conformational change involving an outward movement of an α helix to open the LBS for accommodating the prenyl moiety ([@bib32]). The opening of the LBS is induced by binding to a Rab molecule rather than the prenyl group per se ([@bib14]; [@bib49]). Therefore, RavZ has evolved a GDI-like mechanism to extract LC3-PE from membranes. Taken together, we propose a working model of RavZ function as shown in [Figure 7](#fig7){ref-type="fig"}.10.7554/eLife.23905.018Figure 7.Working model of RavZ-mediated LC3-PE deconjugation on the membrane.RavZ (deep teal) recognizes LC3 molecule (green) on the membrane *via* its LIR2 motif (magenta). RavZ targets to autophagosome membrane by interaction of its C-terminal domain with PI3P (orange) and association of the α3 helix (the helix inserted into the membrane) with membranes. α3 facilitates extraction of the PE moiety (yellow) from the membrane and docking of the fatty acid chains into the lipid-binding site of RavZ. The interaction of the PE moiety with LBS and the LIR2:LC3 binding orient the C-terminal tail into the active site for cleavage. RavZ:LC3 complex was generated by molecular docking using ZDOCK server: an automatic protein docking server (<http://zdock.umassmed.edu>). The LC3^1--120^ structure from Atg4B:LC3 complex (PDB: 2Z0D) was docked onto the structure of RavZ^20-502^ (residues 48--432). The C-terminal residues (115-120) of LC3^1--120^ and catalytic residues (C258, H176 and D197) located in the active site of RavZ were selected as the binding residues. The model was selected from top 10 scoring models. Binding of N-terminal LIR2 loop of RavZ with LC3 was generated by superimposition of the LIR2:LC3 structure onto LC3 in the docking structure.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.018](10.7554/eLife.23905.018)

Materials and methods {#s4}
=====================

Cell lines, chemicals and antibodies {#s4-1}
------------------------------------

MCF7 cells (HTB-22) and HeLa (CCL-2) cells were obtained from ATCC. Human microtubule-associated protein light chain 3B (LC3) were cloned into pEGFP-C1 vector (Clontech) and pEGFP-C1-LC3 plasmid was used to generate human MCF-7 stable cell lines by single-cell Fluorescence-Activated Cell Sorting (FACS). They were tested negative for mycoplasma contamination. The cells were grown in minimum essential medium (MEM) (Sigma-Aldrich Cat\# M4655) supplemented with 10% fetal bovine serum (FBS), 1% sodium pyruvate and 1% non-essential amino acids (NEAA). G418 (200 µg/mL) for the stable cell line. Cell lines were cultured at 37°C in 5% CO~2~. For starvation, cells were first washed with PBS three times and incubated in EBSS (Sigma Cat\# E3024) for 2 hr.

Chemicals for peptide and compound synthesis were obtained from Acros, Aldrich, Avanti, Fluka, Santa Cruz or Novabiochem and used without further purification.

Antibodies used in the study were rabbit anti-LC3B (Cell Signaling Technology Cat\# 2775, RRID:[AB_915950](https://scicrunch.org/resolver/AB_915950)), anti-Cherry (Abcam Cat\# ab125096, RRID:[AB_11133266](https://scicrunch.org/resolver/AB_11133266)) and mouse anti-β-actin (Millipore Cat\# MAB1501, RRID:[AB_2223041](https://scicrunch.org/resolver/AB_2223041)). HRP-conjugated secondary antibodies used for WB were anti-mouse (Dako Cat\# P022602, RRID:[AB_579516](https://scicrunch.org/resolver/AB_579516)) and anti-rabbit (Millipore Cat\# AQ132P, RRID:[AB_92785](https://scicrunch.org/resolver/AB_92785)).

Chemical synthesis {#s4-2}
------------------

Peptides were synthesized employing an Fmoc-based solid phase peptide synthesis strategy using 2-chlorotrityl chloride resin. Protected peptide (0.016 mmol) was lipidated by 1-hexadecanol (16C), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) or 1,2-dihexanoyl-*sn*-glycero-3-phosphoethanolamine (DHPE). All peptides were characterizated by high-resolution mass spectra (HR-MS) ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}). HR-MS were measured on a Thermo Orbitrap coupled to a Thermo Accela HPLC system using electrospray ionization (ESI).

The small nucleophiles, ethanolamine **1** and phosphoethanolamine **2** were purchased from Sigma. Other small nucleophiles, glycerophosphoethanolamine **8** and diacetyl glycerophosphoethanolamine **10** were synthesized as shown in [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}. Subsequently, these compounds were characterizated by NMR and HR-MS ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). ^1^H NMR spectra were recorded on a Varian Mercury Plus 300 MHz spectrometer (300 MHz), a Bruker DRX 400 (400.13 MHz) spectrometer. NMR spectra were calibrated to the solvent signals of DMSO-*d~6~* (δ = 2.50 and 40.45 ppm). All reactions were carried out under an inert atmosphere in dry solvents unless otherwise noted.

Synthesis of LC3 proteins containing different C-terminus modification {#s4-3}
----------------------------------------------------------------------

The lipidated proteins were achieved by performing express protein ligation (EPL) of recombinant LC3-thioester proteins with synthetic lipidated peptides according to our previous method ([@bib47]). LC3 proteins containing soluble fragments of PE lipid were produced using direct aminolysis strategy of protein thioester by a small-molecule nucleophile ([@bib30]; [@bib48]).

Ligation of the DPPE (16:0) or 16-carbon hexanoyl chain modified peptide with MBP-LC3^1--114^ thioester was performed as previously reported ([@bib47]). The ligation of DHPE (6:0) modified peptide with MBP-LC3^1--114^ thioester was performed in absence of the detergent. After incubation overnight at room temperature, the ligated product was purified by size exclusion chromatography (Superdex 200 10/300 GL).

Aminolysis of LC3^1--120^-thioester by small-molecule nucleophile was carried out by the following procedure. 50 µM LC3^1--120^-MESNA thioester was incubated with 0.5 M small molecule nucleophiles in the buffer (100 mM NaH~2~PO~4~, pH 7.2, 50 mM NaCl, 100 mM MPAA) for 48 hr at 4°C. The reaction was subjected to LC-MS analysis. Finally, the solution was dialyzed against dialysis buffer to remove unreacted compound.

Expression and purification {#s4-4}
---------------------------

Plasmids containing RavZ fragments or LC3 proteins were transformed into *E.coli* BL21 (DE3)-LIR cells. Protein expression was induced with 0.2--0.4 mM IPTG and carried out at 20°C overnight. Purification was performed with Äkta prime plus chromatography purification system (GE Healthcare Life Sciences). The cells were harvested and resuspended in breaking buffer containing 1X protease cocktail (Roche Life Science Cat\# 05056489001) or 1 mM PMSF. Cells were then lysed by a Microfluidizer (Microfluidics). All proteins used in this study contain affinity tags (MBP, GST or chitin-binding domain (CBD)) with an extra 6xHis tag fused to its N-terminus. The proteins were initially purified by Ni-NTA-affinity purification using HisTrap HP column (GE Healthcare Life Sciences) eluted with gradient of 0--100% of 500 mM imidazole. To release the protein from the affinity tags, the fusion proteins carrying precision protease or TEV protease cleavage site were cleaved by the corresponding proteases overnight at 4°C. For the chitin fusion proteins with intein tag were cleaved by adding powdered MESNA to a final concentration of 0.5 M and incubation overnight at room temperature to produce the protein thioesters. The cleaved tags were removed with HisTrap HP column, proteins were further purified with size exclusion chromatography using HiLoad 16/60 Superdex 200.

For analytical gel filtration analysis of the complex formation. The experiments were performed on Superdex 200 10/300 GL equipped with ÄKTAFPLC system. Protein samples were previously purified with size exclusion chromatography as a last purification step. Complex formation was done by mixing each of RavZ fragment and LC3^1--119^ with molar ratio of 1:1.5 and incubated at 4°C overnight. 500 µL of proteins or protein complexes were injected to pre-equilibrated column with buffer containing 50 mM HEPES pH 7.5, 50 mM NaCl and 2 mM DTE. The size exclusion chromatography was performed with a flow rate of 0.5 ml/min for 35 min. The standard protein markers containing (thyroglobulin (670 kDa), globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B12 (1.3 kDa)) were run on the same column under identical condition.

Crystallization and structural determination {#s4-5}
--------------------------------------------

For crystallization screening, proteins were screened for crystallization conditions with various crystallization screening kits from QIAGEN. Protein and screening buffer were automatically mixed in ratio 1:1 with 0.1 µL of each by mosquito in crystallization screening plate. The crystallization plates were incubated in the Rock Imager (Formulatrix), an automated imaging system at 277.15 K and 293.15 K. RavZ^1--430^/LC3B^1--119^ complex was crystallized in 0.17 M ammonium acetate, 0.085 M tri sodium citrate pH 5.6, 25.5% PEG4000 and 15% glycerol at 277.15 K. RavZ^1--487^ and RavZ^20-502^ were crystallized in 16% PEG3350, 0.2 M BaCl~2~ and 0.1 M MES pH 5.6 at 277.15 K. LIR2-LC3^1--119^ fusion protein was crystallized in two conditions, as indicated with low-salt and high-salt. The low-salt condition contains 0.1 M citric acid anhydrous pH 4.0 and 1.6 M ammonium sulfate at 293.15 K and high-salt condition contains 0.1 M sodium acetate pH 4.5 and 3 M NaCl at 277.15 K. The crystallization conditions were further optimized by refining concentration of precipitant, salt and pH.

The data were collected at 100 K at PXII-XS10SA beamline in the Swiss Light Source (SLS) Villingen. Data was indexed, processed and scaled with XDS ([@bib16]). RavZ (PDB: 5CQC) and LC3B (PDB: 2ZOD) were used as molecular replacement search models. Molecular replacement and structural refinement were done with PHENIX ([@bib1]) and rebuilt in COOT ([@bib9]). Validation was done with Molprobity ([@bib4]). X-ray data collection and refinement statistics are listed in [Supplementary file 4](#SD4-data){ref-type="supplementary-material"}.

Enzyme kinetics {#s4-6}
---------------

### In vitro LC3-PE cleavage assay {#s4-6-1}

7 µM LC3-DPPE (16:0) or LC3-DHPE (6:0) was incubated with 0.7 µM RavZ at 37°C. At indicated time points, 10 µL sample was taken and subsequently mixed with 4x SDS sample buffer to quench the reaction. Samples were analyzed by SDS-PAGE.

### Kinetic analysis of LC3-PE cleavage by RavZ {#s4-6-2}

Different concentrations of LC3-DPPE (16:0) or LC3-DHPE (6:0) (0.7, 1.1, 2.1, 4.2, 7.0, 10.5, 14.0, 21.0 and 28.0 µM) were mixed with 0.7 µM RavZ concentration. LC3-DPPE (16:0) was incubated with RavZ for 8 min and LC3-DHPE (6:0) for 140 min. The reaction was quenched by SDS loading buffer and samples were analyzed by SDS-PAGE.

### Inhibition assay of LIR2 peptide {#s4-6-3}

LC3-PE (7 µM) was incubated with different concentration of the LIR2 peptide for 1 hr on ice. The mixture was subjected to RavZ (0.7 µM) treatment for 10 min at 37°C and then analyzed by SDS-PAGE. IC~50~ value was calculated using four-parameter logistic function by Origin.

### Quantitative analysis {#s4-6-4}

To quantitatively analyze the SDS-PAGE results, the intensity of the bands on the polyacrylamide gel was measured by determination of the optical density (OD). A density profile was created and the integral was calculated by ImageJ. The percentage of substrate (LC3-PE) was defined for each time point as ([Equation 1](#equ1){ref-type="disp-formula"}):$$Substrate~\left( \% \right) = \frac{OD_{Substrate}}{OD_{Substrate} + ~OD_{Product}} \times 100\%$$

The percentage of substrate was plotted against the RavZ incubation time and the half-time (t~1/2~) of cleaved PE from LC3 was calculated by exponential fitting using *Origin*.

The initial velocity *V* (µM/s) defined as the change in the concentration of cleaved product (LC3^1--119^) was plotted against the concentration of the substrate LC3-PE, *S* (µM). The maximal velocity *V~max ~*and the Michaelis constant *K~m~* were obtained by fitting data to Michaelis-Menten equation. The catalytic constant *k~cat~* was defined as ratio between *V~max~* and enzyme concentration and the catalytic efficiency as ratio between *k~cat~* and *K~m~*.

Mass analysis of modified proteins and cleaved product {#s4-7}
------------------------------------------------------

LC-MS analysis was performed on an Agilent 1100 series chromatography system equipped with an LCQ electrospray mass spectrometer (Finnigan, San Jose) using Jupiter C4 columns (5 μm, 15 × 0.46 cm, 300 Å pore-size) from Phenomenex (Aschaffenburg, Germany). For LC-separations a gradient of buffer B (0.1% formic acid in acetonitrile) in buffer A (0.1% formic acid in water) with a constant flow-rate of 1 mL/min was employed. Upon sample injection, a ratio of 20% buffer B was kept constant for 4 min. Elution was achieved using a linear gradient of 30--80% buffer B in buffer A for 5--15 min followed by a steep gradient (70--90% buffer B) for 15--17 min. The column was extensively flushed for 17--19 min with 90--10% buffer B. Data evaluation was carried out using the Xcalibur software package and MagTran software programs was used for deconvolution of ESI mass spectra ([Supplementary file 3](#SD3-data){ref-type="supplementary-material"}).

Binding affinity measurements {#s4-8}
-----------------------------

### Binding measurements using fluorescence polarization {#s4-8-1}

Fluorescence polarization was performed on Tecan safire II. The LC3 was introduced a single cysteine at the N-terminus for labeling with Tide Fluor 3 (TF3) maleimide dye. 6.25 μM labeled LC3 was titrated with RavZ in the buffer containing 25 mM HEPES, pH 7.2, 25 mM NaCl~2~ and 2 mM DTE. The measurement was carried out in the 384-well plate. Measuring was set in a polarization mode with excitation and emission wavelength at 530 nm and 584 nm, respectively. For binding measurement of FITC-LIR2 peptide with LC3 and its variants as well as GABARAPL1 and GATE16, 2.5 μM FITC-LIR2 was used with the excitation and emission at 470 nm and 525 nm, respectively.

Non-linear binding curves were obtained from plotting the polarization signal against log concentration of the titrants. K~d~ values were obtained by fitting binding curves with a quadratic equation ([Equation 2](#equ2){ref-type="disp-formula"}) using GraFit5.$$F = F_{\min} + \left( {K_{d} + A_{0} + E_{0} - \sqrt{\left( {K_{d} + A_{0} + E_{0}} \right)^{2} - 4A_{0}E_{0}}} \right)\frac{F_{\max} - F_{\min}}{2A_{0}}$$

where ***A~0~*** and ***E~0~*** are the total concentrations (free and bound) of labeled ligand A (LC3) and titrant E (RavZ), respectively. ***F*** is the experimentally observed fluorescence polarization signal, ***F~min~*** is the initial signal at ***E~0~*** = 0, ***F~max~*** is the final signal at ***E~0~*** = ∞.

### Binding measurement using isothermal titration calorimetry (ITC) {#s4-8-2}

The titrant LIR2 peptide with a concentration of 700 µM was injected into 70 µM LC3 with 20 injections at 33°C with the duration and spacing times of 4 s and 60 s, respectively. The experiments were done in the buffer containing 50 mM HEPES pH 7.2, 50 mM NaCl and 2 mM 2-mercaptoethanol. Titration of the buffer into LC3 was used as the blank for background subtraction. The heat release was plotted against the concentration of titrant and subtracted with background, yielding the binding curve. The K~d~ values of the binding were obtained by fitting the final binding curves with a single binding mode using Microcal software.

### Binding measurement using MST {#s4-8-3}

The inactive RavZ (C258A) was labeled with TF3 dye and 2.5 µM of the labeled RavZ (C258A) was added into titrated concentration of MBP-LC3-PE (16:0) or MBP-LC3^1--119^ (41.5 nM to 5.07 nM) in a buffer containing 20 mM HEPES pH 7.2, 25 mM NaCl~2~ and 2 mM DTE. The experiments were done at 28°C. The samples were filled into standard capillaries and measured with a 34% LED and 60% IR-Laser with laser-on time of 30 s and laser-off time of 5 s. The movement of the molecules along the temperature gradient results in a reduction of fluorescence. Plotting the reduction of fluorescence vs. the concentration of the titrants yields a non-linear binding curve. The binding curves were fitted with the nonlinear solution of the law of mass action.

Protein secondary structure estimation using circular dichroism {#s4-9}
---------------------------------------------------------------

CD spectroscopy was acquired using a Jasco J-815 CD spectrometer equipped with a JASCO PTC-423S temperature controller. Proteins were diluted to 0.125 mg/ml in 50 mM phosphate buffer pH 7.5 containing 50 mM NaCl and 2 mM DTE. Protein samples were filled in 0.1 cm quartz cuvette and scan from 195 nm to 260 nm at 25°C, scanning speed was 20 nm/min and CD spectra were accumulated three times. Firstly, CD spectra of protein samples were subtracted by spectra of buffer and smoothed using a FFT filter. The unit of millidegree (***θ***) was conversed to mean residue molar ellipticity ***\[θ\]~MRW~,~λ~***. The ratio of secondary structure elements was calculated with the software CDNN. The database consisting of 33 reference proteins was used in the deconvolution analysis.

Imaging and immunoblotting {#s4-10}
--------------------------

For imaging, MCF7 cells stably expressing GFP-LC3 or HeLa cells were plated at a density of 5.0 × 10^4^ cells per well on µ-Slide 4 Well (Ibidi). GFP-LC3 stable cells were transfected with 250 ng of mCherry-RavZ constructs using X-treme GENE HP DNA transfection reagent. For co-transfection, HeLa cells were co-transfected with each 125 ng of GFP-LC3 and mCherry-RavZ constructs. After 20 hr, live cell imaging was performed in MEM without phenol red (Thermo Fisher Cat\# 51200046) or EBSS (Sigma Cat\# E3024) by using an inverted confocal microscope Leica TCS SP2 or SP5 AOBS equipped with a 63×/1.4 HCX Plan Apo oil immersion lens and a temperature-controlled hood at 37°C and 5% CO~2~. Quantification of the area of GFP-LC3 puncta was performed through Analyze Particles function of ImageJ.

For immunoblotting, GFP-LC3 stable cells were plated at a density of 5.0 × 10^5^ cells per well in a 6‐well plate. Cells were transfected with 1 μg of each plasmid using X-treme GENE HP DNA transfection reagent (Roche Life Science Cat\# 06365244001). For immunoblotting, total cell lysates were prepared by adding cells to RIPA buffer (50 mM Tris pH 7.8, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% sodium dodecyl sulfate (SDS)). Equal amount of proteins was resolved by SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibody overnight at 4°C. After washing 3 times with TBST buffer, membranes were incubated with secondary antibodies conjugated with horseradish peroxidase for 60 min. Signals were visualized with ECL Prime Western Blotting Detection Reagent(Amersham Cat\# 10600001) or SuperSignal Western Blot Enhancer (Thermo Fisher Cat\# 34095) using UltraCruz Autoradiography Films (Santa Cruz Cat\# sc-201696).

LC3-PE membrane extraction assay {#s4-11}
--------------------------------

MCF7 cell membranes were prepared as described ([@bib31]; [@bib32]). GFP-LC3 stable cells were starved in EBSS for 2 hr to induce autophagy. The cells were collected and resuspended in the fractionation buffer (FB buffer, 250 mM Sucrose, 20 mM HEPES (7.4), 10 mM KCl, 1.5 mM MgCl~2~, 1 mM EDTA, 1 mM DTT and protease inhibitor cocktail) on ice for 30 min. The cell solution was homogenized 80 times using Dounce homogenizer. The cell lysate was cleared by centrifugation at 540 g for 5 min. The extract was then loaded onto a 1 mL cushion of sucrose (60% in RB), and centrifuged at 100,000 g for 1 hr in a Optima MAX-XP ultracentrifuge equipped with rotor TLA_100.4 (Beckman Coulter). The buffer--sucrose interface was collected in a minimal volume, and the protein concentration was determined by the Bradford assay.

Different concentrations of RavZ^C258A^ protein were incubated with the membrane fraction (20 µg of membrane protein) in the final assay volume of 100 µL at 37°C for 2 hr. 500 µL of FB buffer was added to each reaction and mixed. Diluted assay mixtures were centrifuged for 1 hr at 100,000 g using the ultracentrifuge equipped with rotor TLA_100.1 (Beckman Coulter). Precipitation of the supernatant was done using TCA/DOC (trichloroacetic acid/sodium deoxycholate) protocol. Briefly, DOC (final concentration 125 µg/ml) and TCA (final concentration 6%) were added to the protein fraction, subsequently. The resulting solution was mixed and incubated on ice for 20 min, and then was centrifuged 15 min in max speed (14,680 rpm). The pellet was washed by cold acetone and dissolved in 1X SDS sample buffer. The samples were resolved on 13% SDS--PAGE gel. Membrane-associated and extracted endogenous LC3-II and GFP-LC3-II were visualized by immunoblotting with anti-LC3 antibody.

For detection of cytosolic LC3-PE level in the RavZ^C258A^ transfected cells, GFP-LC3 stable cells were plated to 6 cm dish at a density of 1.6 × 10^6^ cells per dish. The cells were transfected with 3 μg of plasmid pmCherry-RavZ^C258A^ using X-treme GENE HP DNA transfection reagent. The pmCherry vector also was used as a control. After 24 hr, cells were starved and collected, and resuspended in the FB buffer on ice for 30 min. The cell solution was homogenized 80 times using Dounce homogenizer. The cell lysate was cleared by centrifugation at 540 g for 5 min. The extract (total protein fraction) was then centrifuged at 100,000 g for 1 hr in an Optima MAX-XP ultracentrifuge equipped with rotor TLA_100.1 (Beckman Coulter). The supernatant (cytosolic fraction) was collected and the pellet (membrane fraction) was resuspended in the RIPA buffer. The protein concentration was determined by the Bradford assay. LC3 proteins were visualised by immunoblotting with anti-LC3 antibody.

Quantification and statistical analysis {#s4-12}
---------------------------------------

Results were expressed as mean ± standard deviation of means (SD). The data were assessed by one-way analysis of variance (ANOVA) followed by the Fisher LSD\'s post hoc comparisons. In all statistical comparisons, differences with p\<0.05 were considered significance. Statistical analysis was performed in Origin 9.

Accession codes {#s4-13}
---------------

Atomic coordinates and structure factors have been deposited in the Protein Data Bank under the following accession codes 5MS2 (RavZ^1--431^/LC3B), 5MS5 (low-salt RavZ LIR2-LC3B), 5MS6 (high-salt RavZ LIR2-LC3B), 5MS7 (RavZ^20-502^) and 5MS8 (RavZ^1--487^).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Elucidation of the *Legionella*effector RavZ against host autophagy using semisynthetic LC3 proteins\" for consideration by *eLife*. Your article has been favorably evaluated by Ivan Dikic (Senior Editor) and three reviewers, one of whom, Volker Dötsch (Reviewer \#1), is a member of our Board of Reviewing Editors. The following individuals involved in review of your submission have agreed to reveal their identity: Kim Orth (Reviewer \#2); Hubert Hilbi (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Yang et al. analyze the mode of action of the *Legionella* protein RavZ. This translocated effector protein has previously been shown to irreversibly deconjugate Atg8/LC3-phosphatidylethanolamine (PE), thus inhibiting the autophagy pathway. The authors use semi-synthesis approaches to produce LC3 proteins modified with different PE derivatives. These substrates are then employed to assess binding, catalytic activity and structure-function relationships of the RavZ-LC3 complex. The study shows that RavZ (i) specifically cleaves LC3-DPPE and LC3-DHPE in vitro, (ii) extracts LC3-PE from membranes prior to cleavage, and (iii) binds to LC3 through an N-terminal LIR motif, which is composed of conserved aromatic/hydrophobic amino acids and required for substrate cleavage. Moreover, (iv) the crystal structure of a RavZ:LC3 complex indicated that RavZ forms a lipid binding site homologous to the eukaryotic lipid transfer protein Sec14, and (v) the functional relevance of this lipid binding groove was tested by mutational analysis and in vitro LC3-PE cleavage assays.

All reviewers agreed that this is a very interesting study. However, several points were raised that are listed below. In particular, certain information is missing from some of the figure legends and the model should be improved.

Essential revisions:

1\) \"Apo-protein/-enzyme\" is canonically used to designate a protein/enzyme lacking its non-proteinaceous co-factor. Accordingly, the terms \"apo-structure\", \"apo-RavZ structure\" and \"apo-Sec14 structure\", which are used in the manuscript to describe proteins/structures in absence of a (lipo-)protein binding partner, seems misleading. Please correct.

2\) Figure legend 2 and Figure legend 2 supplements:

Legend to [Figure 2](#fig2){ref-type="fig"}: the acronyms of the LC3-derivatives should be defined: \"EA\", \"pEA\", \"GpEA\", \"DAGpEA\", \"DPPE\" and \"DHPE\".

[Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}: The Atg4B gel is the same one used for the Yang 2013 paper. You can see the same horizontal line on the top left portion of the gel. It would be better to either repeat the experiment or just cite the results in the text, instead of reusing the figure.

[Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}: The cleavage product for the LC3(1-120)-PE(16:0) seems really faint in this gel. Was it possible to accurately quantitate it and was the experiment done in replicates?

3\) [Figure 3A](#fig3){ref-type="fig"}: The panel for extracted untagged-LC3 is missing here.

4\) In [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}: The chromatograms of the complex seem to indicate the existence of several additional peaks (species). What are those peaks?

5\) [Figure 5](#fig5){ref-type="fig"} legend: Is the gray structure in B apo-RavZ? This is not indicated in the legend. Also, the color for the PI3P domain in A is listed as deep-pearl in the legend instead of teal.

6\) Figure legend 6 and Figure legend 6 supplement:

[Figure 6A](#fig6){ref-type="fig"}: Please number the secondary structure elements in the Sec14, the text is impossible to follow without these. The identity of the pink ligand is not indicated anywhere in the figure or the legend.

In addition in legend to [Figure 6](#fig6){ref-type="fig"}: define \"lipid-binding site (LBS)\".

[Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}: It is not clear at all why NEDP1 is used in this alignment and it is not discussed at all in the text. Please explain why the change from Sec14 to NEDP1 and indicate the PDB ID code for NEDP1. It would also be very helpful to number secondary structure elements in A and C as they are discussed in the text.

7\) Figure legend 7 and Figure legend 7 supplement:

[Figure 7](#fig7){ref-type="fig"} legend: A citation should be provided for the ZDOCK server. Also, no details about how the docking was performed are offered here or in the Methods. It would be good to know whether full length or truncated structures were used as input for the docking program.

In addition, omit \"sphere\" -- (orange), (yellow).

The model in [Figure 7](#fig7){ref-type="fig"} oversimplifies the mechanism. The effector is delivered to the host and is targeted to the autophagic membrane via PI3P binding. Once bound, by lateral movement, RavZ finds an LC3-PE molecule, extracts the lipid and cleaves its substrate. LC3 is a soluble protein but what happens to the lipid? As drawn in your model the whole complex becomes soluble and there is no longer PIP3 binding? For the third figure, membrane should be underneath the complex, if it is rotated. RavZ will remain on the membrane via its binding to PI3P -- in search of another substrate.

8\) Methods section 8.2: Binding measurement using isothermal titration calorimetry (ITC). Why was a titration of buffer into RavZ used to measure background? Titration of buffer into LC3 or LIR2 peptide into buffer would be logical choices to control for background. Also, it would be good to show the thermograms and isotherms in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.

9\) In the section \"RavZ extracts LC3-PE from membranes\" the reader does not know that membranes are being tested unless they read the methods. Be more explicit in the explanation of your experiments.

10\) Identification of the potential binding site of the lipid is based on structural comparison and mutational analysis. This is however indirect. A direct identification would be the crystal structure of RavZ with lipidated LC3 or at least a binding study via ITC with lipidated LC3 showing that modified LC3 binds stronger to RavZ than LC3 without lipids. Such a direct interaction study would be much stronger than the current indirect one.

Title:

The title of the manuscript seems somewhat odd: \"Elucidation\" of what? Perhaps, the authors might want to consider \"Elucidation of the anti-autophagy mechanism of the *Legionella*effector RavZ using semisynthetic LC3 proteins\".

10.7554/eLife.23905.037

Author response

*Essential revisions:*

*1) \"Apo-protein/-enzyme\" is canonically used to designate a protein/enzyme lacking its non-proteinaceous co-factor. Accordingly, the terms \"apo-structure\", \"apo-RavZ structure\" and \"apo-Sec14 structure\", which are used in the manuscript to describe proteins/structures in absence of a (lipo-)protein binding partner, seems misleading. Please correct.*

We agree with the reviewers that using the term of Apo-protein might be misleading. Therefore, we now use "free" protein instead of Apo-protein throughout the manuscript.

*2) Figure legend 2 and Figure legend 2 supplements:*

*Legend to [Figure 2](#fig2){ref-type="fig"}: the acronyms of the LC3-derivatives should be defined: \"EA\", \"pEA\", \"GpEA\", \"DAGpEA\", \"DPPE\" and \"DHPE\".*

We have defined the acronyms of the LC3-derivatives in the legend of [Figure 2](#fig2){ref-type="fig"} in the revised manuscript.

*[Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}: The Atg4B gel is the same one used for the Yang 2013 paper. You can see the same horizontal line on the top left portion of the gel. It would be better to either repeat the experiment or just cite the results in the text, instead of reusing the figure.*

The biochemical experiments were repeated three times. The result on Atg4B-mediated cleavage of pro-LC3 and semisynthetic LC3-PE is now replaced by a new figure in the revised manuscript.

*[Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}: The cleavage product for the LC3(1-120)-PE(16:0) seems really faint in this gel. Was it possible to accurately quantitate it and was the experiment done in replicates?*

The experiment was done in triplicates. The bands for lower concentrations are indeed faint. We have now redone the experiments with longer reaction time, in order to produce sufficient amount of product. The error bars are now included in the graph of quantification.

*3) [Figure 3A](#fig3){ref-type="fig"}: The panel for extracted untagged-LC3 is missing here.*

We have now included the extraction of endogenous LC3-II.

*4) In [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}: The chromatograms of the complex seem to indicate the existence of several additional peaks (species). What are those peaks?*

The complexes were formed by mixing the purified proteins of each RavZ fragment with LC3^1-119^ in a molar ratio of 1:1.5 and incubated overnight on ice. The additional peak at later time represents uncomplexed excess LC3^1-119^, as shown in the SDS-PAGE analysis of elution fractions from gel filtration. We have now illustrated the additional peak in the gel filtration profiles and included the SDS-PAGE analysis.

*5) [Figure 5](#fig5){ref-type="fig"} legend: Is the gray structure in B apo-RavZ? This is not indicated in the legend. Also, the color for the PI3P domain in A is listed as deep-pearl in the legend instead of teal.*

Yes, it is an apo-RavZ. It is now illustrated as free RavZ in the legend and PI3P domain is now indicated with teal.

*6) Figure legend 6 and Figure legend 6 supplement:*

*[Figure 6A](#fig6){ref-type="fig"}: Please number the secondary structure elements in the Sec14, the text is impossible to follow without these. The identity of the pink ligand is not indicated anywhere in the figure or the legend.*

The secondary elements (α7-α10) of yeast Sec14 homolog Sfh1 are now labeled. The bound PE (pink ligand) is indicated in the legend.

*In addition in legend to [Figure 6](#fig6){ref-type="fig"}: define \"lipid-binding site (LBS)\".*

Done.

*[Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}: It is not clear at all why NEDP1 is used in this alignment and it is not discussed at all in the text. Please explain why the change from Sec14 to NEDP1 and indicate the PDB ID code for NEDP1. It would also be very helpful to number secondary structure elements in A and C as they are discussed in the text.*

We have pointed out in the text: "The fold of the N-terminal catalytic domain of RavZ is closely related to cysteine proteases in the ubiquitin-like(Ubl)-specific protease (Ulp) family that is specific for de-conjugating Ubl proteins (Mossessova and Lima, 2000; Shen et al., 2005). A similar LBS fold is also found in Ulp proteins (NEDP1, PBD: 2BKR), but this fold is lack of the α3 loop ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"})."

The secondary elements are now indicated in A and C.

*7) Figure legend 7 and Figure legend 7 supplement:*

*[Figure 7](#fig7){ref-type="fig"} legend: A citation should be provided for the ZDOCK server. Also, no details about how the docking was performed are offered here or in the Methods. It would be good to know whether full length or truncated structures were used as input for the docking program.*

We have now added more information in the legend of [Figure 7](#fig7){ref-type="fig"}: "ZDOCK server: an automatic protein docking server (<http://zdock.umassmed.edu>). The LC3^1-120^ structure from Atg4B:LC3 complex (PDB: 2Z0D) was docked onto the structure of RavZ^20-502^ (residues 47-432). The C-terminal residues (115-120) of LC3^1-120^ and catalytic residues (C258, H176 and D197) located in the active site of RavZ were selected as the binding residues. The model was selected from top ten scoring models."

*In addition, omit \"sphere\" -- (orange), (yellow).*

Done.

*The model in [Figure 7](#fig7){ref-type="fig"} oversimplifies the mechanism. The effector is delivered to the host and is targeted to the autophagic membrane via PI3P binding. Once bound, by lateral movement, RavZ finds an LC3-PE molecule, extracts the lipid and cleaves its substrate. LC3 is a soluble protein but what happens to the lipid? As drawn in your model the whole complex becomes soluble and there is no longer PIP3 binding? For the third figure, membrane should be underneath the complex, if it is rotated. RavZ will remain on the membrane via its binding to PI3P -- in search of another substrate.*

We agree with reviewer that the third figure might be misleading. We now exclude it from the model in [Figure 7](#fig7){ref-type="fig"}.

*8) Methods section 8.2: Binding measurement using isothermal titration calorimetry (ITC). Why was a titration of buffer into RavZ used to measure background? Titration of buffer into LC3 or LIR2 peptide into buffer would be logical choices to control for background. Also, it would be good to show the thermograms and isotherms in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}.*

It was a typo. It should be "LC3". We have now corrected it. The experiments were done in triplicates ([Author response image 1](#fig8){ref-type="fig"}). We include one of the ITC data in [Figure 4---figure supplementary 1D](#fig4s1){ref-type="fig"}.10.7554/eLife.23905.023Author response image 1.Interaction analysis of LIR II with LC3 using ITC technique.**DOI:** [http://dx.doi.org/10.7554/eLife.23905.023](10.7554/eLife.23905.023)

*9) In the section \"RavZ extracts LC3-PE from membranes\" the reader does not know that membranes are being tested unless they read the methods. Be more explicit in the explanation of your experiments.*

We have now added some experimental details: "The membrane fraction of cells was incubated with different concentrations of RavZC258A protein. The supernatant was precipitated using TCA/DOC (trichoroacetic acid/sodium deoxycholate). The soluble proteins in supernatant and the membrane-associated proteins were visualized by immunoblotting with anti-LC3 antibody."

*10) Identification of the potential binding site of the lipid is based on structural comparison and mutational analysis. This is however indirect. A direct identification would be the crystal structure of RavZ with lipidated LC3 or at least a binding study via ITC with lipidated LC3 showing that modified LC3 binds stronger to RavZ than LC3 without lipids. Such a direct interaction study would be much stronger than the current indirect one.*

We agree with the reviewers' comment. We have now performed microscale thermophoresis (MST) measurements to compare the direct interaction of RavZ with LC3-PE and LC3. To make LC3-PE soluble in solution without detergent, MBP tag was left intact. The measurements showed that RavZ^C258A^ binds to MBP-LC3-PE and MBP-LC3^1-119^ with dissociation constants (K~d~) of 23 ± 4 nM and 69 ± 5 nM, respectively, which suggests that RavZ binds to lipidated LC3 in 3 times higher affinity than unlipidated LC3. Therefore, the thermodynamic driving force for RavZ extraction is modest but still favorable. We have now added the discussion in the text.

It should be noted that the function of the LBS has been demonstrated by in vitro and in vivo cleavage and extraction assay ([Figure 3---figure supplementary 1C, 1D](#fig3s1){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}).10.7554/eLife.23905.024Author response image 2.MST measurements of binding of RavZ(C258A) with MBP-LC3^1-119^ (4 replicated experiments).**DOI:** [http://dx.doi.org/10.7554/eLife.23905.024](10.7554/eLife.23905.024)10.7554/eLife.23905.025Author response image 3.MST measurments of binding of RavZ(C258A) with MBP-LC3-PE (4 replicated experiments).**DOI:** [http://dx.doi.org/10.7554/eLife.23905.025](10.7554/eLife.23905.025)

*Title:*

*The title of the manuscript seems somewhat odd: \"Elucidation\" of what? Perhaps, the authors might want to consider \"Elucidation of the anti-autophagy mechanism of the Legionella effector RavZ using semisynthetic LC3 proteins\".*

We have now changed the title.

[^1]: These authors contributed equally to this work.
